Atea Pharmaceuticals Inc

NASDAQ:AVIR   3:41:53 PM EDT
6.56
-0.02 (-0.38%)
Products

Atea Pharmaceuticals Introduces New Strategic Clinical Development Program For At-527 In Covid-19

Published: 12/14/2021 22:06 GMT
Atea Pharmaceuticals Inc (AVIR) - Atea Pharmaceuticals Introduces New Strategic Clinical Development Program for At-527 in Covid-19.
Atea Pharmaceuticals Inc - Expects to Provide a More Detailed Update on Its Strategy and New Development Plan in 2022.
Atea Pharmaceuticals Inc - Will Continue to Advance Global At-527 Phase 2 Trial.
Atea Pharmaceuticals - Initiating Preclinical in Vitro Combination Studies of At-527, Other Compounds to Evaluate Additive and Synergistic Benefits.
Atea Pharmaceuticals Inc - in Addition to Morningsky, Follow-on Meadowspring Trial Will Also Be Closed Out.
Atea Pharmaceuticals Inc - Strategic Collaboration With Roche Will Be Terminated on February 10, 2022.
Atea Pharmaceuticals Inc - Expanding Development Program to Maximize At-527's Profile for Potential Use in Combination Therapy.